Galapagos NV: business update: http://t.co/6w1jppWE
posted 6 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Devgen (Euronext Brussels: DEVG) and Syngenta today announced a six-year global license and research agreement. The partnership will enable Syngenta to add RNA interference (RNAi) technology to its crop protection pipeline. As of April 2013, the two companies will jointly develop new biological insect control solutions based on RNAi technology. read more
Galapagos NV (Euronext: GLPG) and Servier announced today the achievement of milestones under their alliance agreement in osteoarthritis. These milestones trigger payments to Galapagos totalling €3.5 million, which will contribute to the Company's 2011 financial results. read more
Along with 6 leading research and knowledge centers across Europe, Applied Maths has entered into a consortium to develop a methodology for rapid and accurate diagnostics and genotyping of bacterial pathogens based upon Next Generation Sequencing. The consortium has successfully applied for a EU research project, Patho-NGen-Trace, which was launched on 1 January 2012. The project will run for 54 months and receive nearly 6 million Euros in funding from the European Union’s 7th Framework Programme. The international consortium consists of leading knowledge centers in the field of clinical microbiology, such as the Westfälische Wilhelms-University Muenster, the University of Oxford and the Research Center Borstel (scientific project coordinator), and expert enterprises in this area, including Applied Maths NV, Genoscreen SAS, Piext BV (representing OpGen, Inc. in Europe) and Ridom GmbH. read more
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces today that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire. read more
Abbott (NYSE: ABT) and Galapagos (Euronext: GLPG) announced today that they have entered into a global collaboration to develop and commercialize an oral, next-generation JAK1 inhibitor in Phase II development with the potential to treat multiple autoimmune diseases. read more
Q-Biologicals, a biotech company focused on providing services in the field of process development and manufacturing of recombinant proteins, viruses and live cells, announces that it has entered into a service framework agreement with Bayer CropScience to produce and purify recombinant proteins for Bayer. Production of two recombinant proteins has already been commissioned. read more
Galapagos NV (Euronext: GLPG) announced today that GlaxoSmithKline has exercised its option to exclusively license investigational compound GLPG0778 and its corresponding back-up compound GLPG0555, both discovered and developed within GSKs immuno-inflammatory alliance with Galapagos. GSK will have the right to continue the clinical development of these candidate compounds. Galapagos will receive an option fee payment of single-digit million Euros from GSK, which contributes to 2011 Group revenues. Galapagos is eligible, without further financial investment from Galapagos, to receive from GSK more than €34M in future milestones plus royalties on these two compounds. read more
ALZPROTECT, société biopharmaceutique engagée dans le développement de médicaments pour le traitement de la maladie d’Alzheimer, annonce aujourd’hui la sélection du labex DISTALZ sur la maladie d'Alzheimer qui vient d'être retenu dans le cadre de la seconde vague d'appel à projets des Labex lancée dans le cadre du Plan « Investissements d'Avenir » du Grand Emprunt. Alzprotect est directement associée à DISTALZ au travers d’une collaboration. read more
> VIB and BASF Plant Science jointly develop TopYield Technology > Largest collaboration VIB has entered in the field of plant biotechnology > Cooperation supported by Flemish government agency IWT read more
